Turnstone Biologics Corp.
TSBXDelisted Aug 11, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764974
Turnstone Biologics Corp. was delisted on Aug 11, 2025; its insiders filed their last Form 4 on Aug 12, 2025; 23 institutions reported holding it in 13F filings for Q2 2025, worth $3.03M in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in Turnstone Biologics Corp. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
TSBX is no longer listed, so this page shows Q2 2025. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 23
- 0 vs. Q1 2025
- Shares held
- 8.43M
- −1.96M (−18.8%) vs. Q1 2025
- Total value
- $3.03M
- −$1.23M (−28.9%) vs. Q1 2025
- New holders
- 3
- 4 more added
- Sold out
- 3
- 8 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TSBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 23 | $3.03M |
| Q1 2025 | 23 | $4.26M |
| Q4 2024 | 28 | $5.51M |
| Q3 2024 | 24 | $6.37M |
| Q2 2024 | 47 | $33.3M |
| Q1 2024 | 40 | $35.0M |
| Q4 2023 | 36 | $33.1M |
| Q3 2023 | 35 | $48.0M |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Turnstone Biologics Corp.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 3,099,265 | $1.11M | 0.03% | 00.0% | Unchanged |
| FMR LLC | 1,133,987 | $407.1K | 0.00% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,103,386 | $396.1K | 0.30% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 895,824 | $321.6K | 1.64% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 816,923 | $293.3K | 0.00% | −62,010−7.1% | Reduced |
| 72 Investment Holdings, LLC | 549,980 | $197.4K | 0.52% | 00.0% | Unchanged |
| Citadel Advisors LLC | 208,887 | $75.0K | 0.00% | +208,887 | New |
| Geode Capital Management, LLC | 130,077 | $46.7K | 0.00% | −6,703−4.9% | Reduced |
| Deltec Asset Management LLC | 106,057 | $38.1K | 0.01% | +106,057 | New |
| Vanguard Group Inc | 83,926 | $30.1K | 0.00% | −431,161−83.7% | Reduced |
| Susquehanna International Group, LLP | 79,305 | $28.5K | 0.00% | +54,000+213.4% | Added |
| HRT Financial LP | 55,859 | $20.0K | 0.00% | +43,776+362.3% | Added |
| Renaissance Technologies LLC | 47,100 | $16.9K | 0.00% | +6,900+17.2% | Added |
| GTS Securities LLC | 45,163 | $16.2K | 0.00% | +45,163 | New |
| XTX Topco Ltd | 37,786 | $13.6K | 0.00% | +2,045+5.7% | Added |
| Northern Trust Corp | 18,405 | $6.61K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 16,430 | $4.00K | 0.00% | −1,403−7.9% | Reduced |
| Tower Research Capital LLC (TRC) | 4,741 | $1.70K | 0.00% | −20−0.4% | Reduced |
| BlackRock, Inc. | 1,066 | $383 | 0.00% | −41,334−97.5% | Reduced |
| JPMorgan Chase & Co | 158 | $57 | 0.00% | −38−19.4% | Reduced |
| Bank of America Corp | 150 | $54 | 0.00% | −891,381−100.0% | Reduced |
| BNP Paribas Arbitrage, SA | 121 | $43 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 71 | $25 | 0.00% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −932,348−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −38,858−100.0% | Sold out |
| Nordwand Advisors, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |